Tarsus Pharmaceuticals

Q2 FY2026 EarningsQ2 FY26 beat consensus across the top line with revenue of $173.9M vs. $169.5M expected, driven by a 69% YoY surge in XDEMVY net product sales. However, the GAAP EPS loss of $0.43 was significantly wider than the expected $0.20 loss, primarily due to aggressive SG&A spending on DTC campaigns and R&D pipeline expansion. Management raised full-year FY26 XDEMVY sales guidance to $685-705M, well above the underlying quarterly run-rate, signaling continued commercial momentum.